Trial Profile
Phase III multicenter, randomized, double-blind placebo-controlled outpatient study of efficacy, tolerability, and safety of once-daily atomoxetine hydrochloride versus placebo in Russian children and adolescents with attention-deficit/hyperactivity disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2006
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 11 Oct 2006 New trial record.